Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 432 entries
Sorted by: Best Match Show Resources per page
Long-term stability of ganciclovir in polypropylene containers at room temperature.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Guichard N, Bonnabry P, Rudaz S, Fleury-Souverain S.
PMID: 28975863
J Oncol Pharm Pract. 2017 Jan 01;1078155217732629. doi: 10.1177/1078155217732629. Epub 2017 Jan 01.

Purpose Ganciclovir is increasingly provided by hospital pharmacy production unit in a ready-to-use form, in order to improve the safety of healthcare workers and the efficiency of the organisation. The objective of this study was to develop a stability-indicating...

Cite
Guichard N, Bonnabry P, Rudaz S, et al. Long-term stability of ganciclovir in polypropylene containers at room temperature. J Oncol Pharm Pract. 2017;1078155217732629doi: 10.1177/1078155217732629.
Guichard, N., Bonnabry, P., Rudaz, S., & Fleury-Souverain, S. (2017). Long-term stability of ganciclovir in polypropylene containers at room temperature. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 1078155217732629. https://doi.org/10.1177/1078155217732629
Guichard, Nicolas, et al. "Long-term stability of ganciclovir in polypropylene containers at room temperature." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. (2017): 1078155217732629. doi: https://doi.org/10.1177/1078155217732629
Guichard N, Bonnabry P, Rudaz S, Fleury-Souverain S. Long-term stability of ganciclovir in polypropylene containers at room temperature. J Oncol Pharm Pract. 2017 Jan 01;1078155217732629. doi: 10.1177/1078155217732629. Epub 2017 Jan 01. PMID: 28975863.
Copy Download .nbib Format: NLM
Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Ecancermedicalscience

Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G.
PMID: 25729426
Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015.

Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections, treatment of Lyme disease and eradication of gastric infection with Helicobacter pylori. Extensive preclinical and clinical data...

Cite
Van Nuffel AM, Sukhatme V, Pantziarka P, et al. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience. 2015;9:513doi: 10.3332/ecancer.2015.513.
Van Nuffel, A. M., Sukhatme, V., Pantziarka, P., Meheus, L., Sukhatme, V. P., & Bouche, G. (2015). Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience, 9513. https://doi.org/10.3332/ecancer.2015.513
Van Nuffel, An Mt, et al. "Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent." Ecancermedicalscience vol. 9 (2015): 513. doi: https://doi.org/10.3332/ecancer.2015.513
Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015. PMID: 25729426; PMCID: PMC4341996.
Copy Download .nbib Format: NLM
Improved pharmacy department workflow with new method of order entry for single-agent, high-dose methotrexate.

Hospital pharmacy

Kintzel PE, VanDyke TH, Athmann PW, Mills LB, Bonter MP, Bremer MW, Dougherty ML, Foster RW, Knight SK, Slot MG, Steinmetz-Malato LL.
PMID: 25673893
Hosp Pharm. 2014 Dec;49(11):1039-43. doi: 10.1310/hjp4911-1039.

PURPOSE: To determine whether a process change impacted the proportion of orders for single-agent, high-dose methotrexate entered by chemotherapy pharmacists instead of general pharmacy staff. Coordination of antiemetic premedication and leucovorin rescue with the new method of order entry...

Cite
Kintzel PE, VanDyke TH, Athmann PW, et al. Improved pharmacy department workflow with new method of order entry for single-agent, high-dose methotrexate. Hosp Pharm. 2014;49(11):1039-43doi: 10.1310/hjp4911-1039.
Kintzel, P. E., VanDyke, T. H., Athmann, P. W., Mills, L. B., Bonter, M. P., Bremer, M. W., Dougherty, M. L., Foster, R. W., Knight, S. K., Slot, M. G., & Steinmetz-Malato, L. L. (2014). Improved pharmacy department workflow with new method of order entry for single-agent, high-dose methotrexate. Hospital pharmacy, 49(11), 1039-43. https://doi.org/10.1310/hjp4911-1039
Kintzel, Polly E, et al. "Improved pharmacy department workflow with new method of order entry for single-agent, high-dose methotrexate." Hospital pharmacy vol. 49,11 (2014): 1039-43. doi: https://doi.org/10.1310/hjp4911-1039
Kintzel PE, VanDyke TH, Athmann PW, Mills LB, Bonter MP, Bremer MW, Dougherty ML, Foster RW, Knight SK, Slot MG, Steinmetz-Malato LL. Improved pharmacy department workflow with new method of order entry for single-agent, high-dose methotrexate. Hosp Pharm. 2014 Dec;49(11):1039-43. doi: 10.1310/hjp4911-1039. PMID: 25673893; PMCID: PMC4319804.
Copy Download .nbib Format: NLM
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?.

Journal of Cancer

Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K.
PMID: 25767606
J Cancer. 2015 Feb 23;6(4):360-6. doi: 10.7150/jca.11308. eCollection 2015.

PURPOSE: Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Furthermore, somatostatin (SST) receptors (SSTR1, 2A and B, 3, 4...

Cite
Domvri K, Bougiouklis D, Zarogoulidis P, et al. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. J Cancer. 2015;6(4):360-6doi: 10.7150/jca.11308.
Domvri, K., Bougiouklis, D., Zarogoulidis, P., Porpodis, K., Xristoforidis, M., Liaka, A., Eleutheriadou, E., Lampaki, S., Lazaridis, G., Organtzis, J., Kyriazis, G., Hohenforst-Schmidt, W., Tsirgogianni, K., Karavasilis, V., Baka, S., Darwiche, K., Freitag, L., Trakada, G., & Zarogoulidis, K. (2015). Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. Journal of Cancer, 6(4), 360-6. https://doi.org/10.7150/jca.11308
Domvri, Kalliopi, et al. "Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?." Journal of Cancer vol. 6,4 (2015): 360-6. doi: https://doi.org/10.7150/jca.11308
Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. J Cancer. 2015 Feb 23;6(4):360-6. doi: 10.7150/jca.11308. eCollection 2015. PMID: 25767606; PMCID: PMC4349876.
Copy Download .nbib Format: NLM
High-throughput online solid-phase extraction tandem mass spectrometry: Is it right for your clinical laboratory?.

Clinical biochemistry

Jannetto PJ, Langman LJ.
PMID: 27129800
Clin Biochem. 2016 Sep;49(13):1032-4. doi: 10.1016/j.clinbiochem.2016.04.012. Epub 2016 Apr 27.

With increasing patient volumes and growing demands for rapid turnaround on many clinical tests, there is a demand for high-throughput technologies. High-Throughput Online Solid-Phase Extraction Tandem Mass Spectrometry is an example of one technology that can achieve these desired...

Cite
Jannetto PJ, Langman LJ. High-throughput online solid-phase extraction tandem mass spectrometry: Is it right for your clinical laboratory?. Clin Biochem. 2016;49(13):1032-4doi: 10.1016/j.clinbiochem.2016.04.012.
Jannetto, P. J., & Langman, L. J. (2016). High-throughput online solid-phase extraction tandem mass spectrometry: Is it right for your clinical laboratory?. Clinical biochemistry, 49(13), 1032-4. https://doi.org/10.1016/j.clinbiochem.2016.04.012
Jannetto, Paul J, and Langman, Loralie J. "High-throughput online solid-phase extraction tandem mass spectrometry: Is it right for your clinical laboratory?." Clinical biochemistry vol. 49,13 (2016): 1032-4. doi: https://doi.org/10.1016/j.clinbiochem.2016.04.012
Jannetto PJ, Langman LJ. High-throughput online solid-phase extraction tandem mass spectrometry: Is it right for your clinical laboratory?. Clin Biochem. 2016 Sep;49(13):1032-4. doi: 10.1016/j.clinbiochem.2016.04.012. Epub 2016 Apr 27. PMID: 27129800.
Copy Download .nbib Format: NLM
Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Journal of translational science

Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.
PMID: 27076919
J Transl Sci. 2016;2(2):117-124. doi: 10.15761/JTS.1000127. Epub 2016 Mar 05.

Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid...

Cite
Ishiguro K, Zhu YL, Lin ZP, et al. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2(2):117-124doi: 10.15761/JTS.1000127.
Ishiguro, K., Zhu, Y. L., Lin, Z. P., Penketh, P. G., Shyam, K., Zhu, R., Baumann, R. P., Sartorelli, A. C., Rutherford, T. J., & Ratner, E. S. (2016). Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. Journal of translational science, 2(2), 117-124. https://doi.org/10.15761/JTS.1000127
Ishiguro, Kimiko, et al. "Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines." Journal of translational science vol. 2,2 (2016): 117-124. doi: https://doi.org/10.15761/JTS.1000127
Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2(2):117-124. doi: 10.15761/JTS.1000127. Epub 2016 Mar 05. PMID: 27076919; PMCID: PMC4827869.
Copy Download .nbib Format: NLM
Effect of α-Tocopherol on Lipid Peroxidation Caused by Cisplatin in Rat Kidney.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Bolaman Z, Köseoğlu MH, Demir S, Kadıköylü G, Barutca S, Atalay H, Aslan D.
PMID: 27265333
Turk J Haematol. 2003 Mar 05;20(1):35-8.

Cisplatin (CDDP) is one of the most commonly used antineoplastic agents in current clinical practice. The major toxicities of CDDP are nonhaematological as nephrotoxicity and ototoxicity. Free oxygen radicals are known to play major role in CDDP-induced acute renal...

Cite
Bolaman Z, Köseoğlu MH, Demir S, et al. α-Tokoferolün Sıçan Böbreğinde Sisplatinin Yol Açtığı Lipid Peroksidasyonuna Etkisi. Effect of α-Tocopherol on Lipid Peroxidation Caused by Cisplatin in Rat Kidney. Turk J Haematol. 2003;20(1):35-8
Bolaman, Z., Köseoğlu, M. H., Demir, S., Kadıköylü, G., Barutca, S., Atalay, H., & Aslan, D. (2003). α-Tokoferolün Sıçan Böbreğinde Sisplatinin Yol Açtığı Lipid Peroksidasyonuna Etkisi. Effect of α-Tocopherol on Lipid Peroxidation Caused by Cisplatin in Rat Kidney. Turkish journal of haematology : official journal of Turkish Society of Haematology, 20(1), 35-8.
Bolaman, Zahit, et al. "α-Tokoferolün Sıçan Böbreğinde Sisplatinin Yol Açtığı Lipid Peroksidasyonuna Etkisi." Effect of α-Tocopherol on Lipid Peroxidation Caused by Cisplatin in Rat Kidney. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 20,1 (2003): 35-8.
Bolaman Z, Köseoğlu MH, Demir S, Kadıköylü G, Barutca S, Atalay H, Aslan D. α-Tokoferolün Sıçan Böbreğinde Sisplatinin Yol Açtığı Lipid Peroksidasyonuna Etkisi. Effect of α-Tocopherol on Lipid Peroxidation Caused by Cisplatin in Rat Kidney. Turk J Haematol. 2003 Mar 05;20(1):35-8. PMID: 27265333.
Copy Download .nbib Format: NLM
Oral Antineoplastic Agents: Assessing the Delay in Care.

Chemotherapy research and practice

Anders B, Shillingburg A, Newton M.
PMID: 26605087
Chemother Res Pract. 2015;2015:512016. doi: 10.1155/2015/512016. Epub 2015 Oct 28.

The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is written by the provider and when the medication is received by the patient and to identify risk factors that...

Cite
Anders B, Shillingburg A, Newton M. Oral Antineoplastic Agents: Assessing the Delay in Care. Chemother Res Pract. 2015;2015:512016doi: 10.1155/2015/512016.
Anders, B., Shillingburg, A., & Newton, M. (2015). Oral Antineoplastic Agents: Assessing the Delay in Care. Chemotherapy research and practice, 2015512016. https://doi.org/10.1155/2015/512016
Anders, Brandi, et al. "Oral Antineoplastic Agents: Assessing the Delay in Care." Chemotherapy research and practice vol. 2015 (2015): 512016. doi: https://doi.org/10.1155/2015/512016
Anders B, Shillingburg A, Newton M. Oral Antineoplastic Agents: Assessing the Delay in Care. Chemother Res Pract. 2015;2015:512016. doi: 10.1155/2015/512016. Epub 2015 Oct 28. PMID: 26605087; PMCID: PMC4641173.
Copy Download .nbib Format: NLM
26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines.

Cancers

Seoane S, Bermudez MA, Sendon-Lago J, Martinez-Ordoñez A, Abdul-Hadi S, Maestro M, Mouriño A, Perez-Fernandez R.
PMID: 24378752
Cancers (Basel). 2013 Dec 27;6(1):67-78. doi: 10.3390/cancers6010067.

It has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and some of its analogues have antitumor activity. 1,25D labeled with deuterium (26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) quantification. In...

Cite
Seoane S, Bermudez MA, Sendon-Lago J, et al. 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers (Basel). 2013;6(1):67-78doi: 10.3390/cancers6010067.
Seoane, S., Bermudez, M. A., Sendon-Lago, J., Martinez-Ordoñez, A., Abdul-Hadi, S., Maestro, M., Mouriño, A., & Perez-Fernandez, R. (2013). 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers, 6(1), 67-78. https://doi.org/10.3390/cancers6010067
Seoane, Samuel, et al. "26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines." Cancers vol. 6,1 (2013): 67-78. doi: https://doi.org/10.3390/cancers6010067
Seoane S, Bermudez MA, Sendon-Lago J, Martinez-Ordoñez A, Abdul-Hadi S, Maestro M, Mouriño A, Perez-Fernandez R. 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers (Basel). 2013 Dec 27;6(1):67-78. doi: 10.3390/cancers6010067. PMID: 24378752; PMCID: PMC3980618.
Copy Download .nbib Format: NLM
Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report.

The journal of breast health

Kılıç MÖ, Yalaza M, Bilgiç Cİ, Dener C.
PMID: 28331700
J Breast Health. 2015 Apr 01;11(2):95-97. doi: 10.5152/tjbh.2015.1879. eCollection 2015 Apr.

Paclitaxel and docetaxel are antineoplastic drugs derived from the yew tree, Taxus brevifolia. They are the members of the taxane family and act by inhibiting mitotic activity due to the suppression of microtubule depolymerization. They are used in the...

Cite
Kılıç MÖ, Yalaza M, Bilgiç Cİ, et al. Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report. J Breast Health. 2015;11(2):95-97doi: 10.5152/tjbh.2015.1879.
Kılıç, M. �. �., Yalaza, M., Bilgiç, C. �. �., & Dener, C. (2015). Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report. The journal of breast health, 11(2), 95-97. https://doi.org/10.5152/tjbh.2015.1879
Kılıç, Murat Özgür, et al. "Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report." The journal of breast health vol. 11,2 (2015): 95-97. doi: https://doi.org/10.5152/tjbh.2015.1879
Kılıç MÖ, Yalaza M, Bilgiç Cİ, Dener C. Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report. J Breast Health. 2015 Apr 01;11(2):95-97. doi: 10.5152/tjbh.2015.1879. eCollection 2015 Apr. PMID: 28331700; PMCID: PMC5351495.
Copy Download .nbib Format: NLM
xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies.

OncoTargets and therapy

Martinez-Serra J, Gutierrez A, Muñoz-Capó S, Navarro-Palou M, Ros T, Amat JC, Lopez B, Marcus TF, Fueyo L, Suquia AG, Gines J, Rubio F, Ramos R, Besalduch J.
PMID: 24959085
Onco Targets Ther. 2014 Jun 12;7:985-94. doi: 10.2147/OTT.S62887. eCollection 2014.

The xCELLigence system is a new technological approach that allows the real-time cell analysis of adherent tumor cells. To date, xCELLigence has not been able to monitor the growth or cytotoxicity of nonadherent cells derived from hematological malignancies. The...

Cite
Martinez-Serra J, Gutierrez A, Muñoz-Capó S, et al. xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies. Onco Targets Ther. 2014;7:985-94doi: 10.2147/OTT.S62887.
Martinez-Serra, J., Gutierrez, A., Muñoz-Capó, S., Navarro-Palou, M., Ros, T., Amat, J. C., Lopez, B., Marcus, T. F., Fueyo, L., Suquia, A. G., Gines, J., Rubio, F., Ramos, R., & Besalduch, J. (2014). xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies. OncoTargets and therapy, 7985-94. https://doi.org/10.2147/OTT.S62887
Martinez-Serra, Jordi, et al. "xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies." OncoTargets and therapy vol. 7 (2014): 985-94. doi: https://doi.org/10.2147/OTT.S62887
Martinez-Serra J, Gutierrez A, Muñoz-Capó S, Navarro-Palou M, Ros T, Amat JC, Lopez B, Marcus TF, Fueyo L, Suquia AG, Gines J, Rubio F, Ramos R, Besalduch J. xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies. Onco Targets Ther. 2014 Jun 12;7:985-94. doi: 10.2147/OTT.S62887. eCollection 2014. PMID: 24959085; PMCID: PMC4061162.
Copy Download .nbib Format: NLM
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.

SpringerPlus

Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD.
PMID: 24926422
Springerplus. 2014 May 21;3:259. doi: 10.1186/2193-1801-3-259. eCollection 2014.

PURPOSE: We sought to compare the economic impact of treatment-related adverse events (AEs) in patients with metastatic breast cancer (mBC) using taxane- or capecitabine-based treatment regimens as either first- or second-line (FL or SL) therapy in the US.METHODS: We...

Cite
Hansen RN, Ramsey SD, Lalla D, et al. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014;3:259doi: 10.1186/2193-1801-3-259.
Hansen, R. N., Ramsey, S. D., Lalla, D., Masaquel, A., Kamath, T., Brammer, M., Hurvitz, S. A., & Sullivan, S. D. (2014). Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. SpringerPlus, 3259. https://doi.org/10.1186/2193-1801-3-259
Hansen, Ryan N, et al. "Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens." SpringerPlus vol. 3 (2014): 259. doi: https://doi.org/10.1186/2193-1801-3-259
Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014 May 21;3:259. doi: 10.1186/2193-1801-3-259. eCollection 2014. PMID: 24926422; PMCID: PMC4047276.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 432 entries